Enlarging residual mass after treatment of a nonseminomatous germ cell tumor: growing teratoma syndrome or cancer recurrence?

PubWeight™: 0.94‹?›

🔗 View Article (PMID 17906212)

Published in J Clin Oncol on October 01, 2007

Authors

Nicolas Aide1, François Comoz, Emmanuel Sevin

Author Affiliations

1: Nuclear Medicine Department, and Bioticla Unit, GRECAN, François Baclesse Comprehensive Cancer Center and Caen University, Caen, France.

Articles by these authors

Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. J Clin Oncol (2014) 6.64

Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer (2007) 2.34

Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. Lancet Oncol (2011) 2.17

Efficiency of [(18)F]FDG PET in characterising renal cancer and detecting distant metastases: a comparison with CT. Eur J Nucl Med Mol Imaging (2003) 2.00

Early loss of two renal grafts obtained from the same donor: role of ecstasy? Transplantation (2005) 1.50

Unusual short-term complete response to two regimens of cytotoxic chemotherapy in a patient with poorly differentiated thyroid carcinoma. J Clin Endocrinol Metab (2012) 1.42

Cutaneous amyloidosis and possible association with systemic amyloidosis. Int J Dermatol (2002) 1.10

Apical-to-basolateral transport of amyloid-β peptides through blood-brain barrier cells is mediated by the receptor for advanced glycation end-products and is restricted by P-glycoprotein. J Alzheimers Dis (2010) 0.96

Modelling the neurovascular unit and the blood-brain barrier with the unique function of pericytes. Curr Neurovasc Res (2011) 0.92

Epidermodysplasia verruciformis in a patient with HIV infection: no response to highly active antiretroviral therapy. Int J Dermatol (2003) 0.87

Actin, gelsolin and filamin-A are dynamic actors in the cytoskeleton remodelling contributing to the blood brain barrier phenotype. Proteomics (2009) 0.85

Increased HIF-1α expression correlates with cell proliferation and vascular markers CD31 and VEGF-A in uveal melanoma. Invest Ophthalmol Vis Sci (2014) 0.85

Transcriptional profiles of receptors and transporters involved in brain cholesterol homeostasis at the blood-brain barrier: use of an in vitro model. Brain Res (2008) 0.84

Influence of surface charge and inner composition of porous nanoparticles to cross blood-brain barrier in vitro. Int J Pharm (2007) 0.82

Urogenital manifestations in Wegener granulomatosis: a study of 11 cases and review of the literature. Medicine (Baltimore) (2012) 0.82

Bexarotene Promotes Cholesterol Efflux and Restricts Apical-to-Basolateral Transport of Amyloid-β Peptides in an In Vitro Model of the Human Blood-Brain Barrier. J Alzheimers Dis (2015) 0.81

A simple method for assessing free brain/free plasma ratios using an in vitro model of the blood brain barrier. PLoS One (2013) 0.80

[Clinical aspects of human polyomaviruses in renal transplantation]. Presse Med (2003) 0.80

Metastatic renal cancer: evolution of five complete response cases after the antiangiogenic discontinuation. Bull Cancer (2011) 0.80

Pairwise comparison of 18F-FDG and 18F-FCH PET/CT in prostate cancer patients with rising PSA and known or suspected second malignancy. Nucl Med Commun (2016) 0.79

Recurrence of ANCA-positive glomerulonephritis immediately after renal transplantation. Am J Kidney Dis (2003) 0.78

Case study: adapting in vitro blood-brain barrier models for use in early-stage drug discovery. Drug Discov Today (2011) 0.77

Endothelial damage in all types of T-lymphocyte-mediated drug-induced eruptions. Arch Dermatol (2011) 0.77

Association of pegylated liposomal doxorubicin and ifosfamide in early recurrent ovarian cancer patients: a multicenter phase II trial. Gynecol Oncol (2009) 0.77

Clinical benefits of non-taxane chemotherapies in unselected patients with symptomatic metastatic castration-resistant prostate cancer after docetaxel: the GETUG-P02 study. BJU Int (2015) 0.76

Sorafenib increases 18-FDG colic uptake: demonstration in patients with differentiated thyroid cancer. EJNMMI Res (2012) 0.75

[Interstitial mycosis fungoid: a rare variant of mycosis fungoids. Two cases]. Ann Pathol (2011) 0.75

Skin manifestations in CD4+, CD56+ malignancies. Eur J Dermatol (2003) 0.75

[Management of adverse effects of targeted therapy toxicities in oncology]. Rev Prat (2012) 0.75